Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of the probiotic food supplement Vivomixx in the prevention
of bone loss occurring in post menopausal women with breast cancer treated with an aromatase
inhibitor. Half of the participants will receive Vivomixx while the other half will receive a
placebo. The primary endpoint is to assess changes of bone turnover markers during the period
of 6 months.